## AIM
To describe the indication, ordering, administration and documentation of Thrombotrol VF

## DESCRIPTION
Thrombotrol®-VF (Antithrombin III Concentrate)

## SPECIFICATIONS
Purified human antithrombin III (ATIII) 1000IU per vial, also contains ≤300 mg human plasma proteins (which include less than 1.7 mg of histidine-rich glycoprotein, 0.12 mg platelet factor 4, and 0.06 U of factor XI), 76 mg sodium, 38 mg citrate and 96 mg chloride. [Thrombotrol®-VF Product Information](#)

## VIAL SIZE
Each vial of Thrombotrol®-VF nominally contains 1000 IU of ATIII.

## INDICATIONS
Indicated in patients with hereditary deficiency of anti-thrombin for:
- Prophylaxis for the prevention of thrombosis and pulmonary embolism, in surgery, pregnancy and childbirth.
- Therapeutic administration, in thrombosis or pulmonary embolism.

## CONTRAINDICATIONS AND PRECAUTIONS
Thrombotrol®-VF should not be used if there is a history of allergy to this type of product.

## CONSUMER INFORMATION
[Thrombotrol®-VF Consumer Medicine Information](#)

## CONSENT
Written consent is required as Thrombotrol®-VF is manufactured from pooled human plasma. Refer to Transfusion Medicine Protocol [WNHS Blood Product Prescription, Informed Consent. And Refusal](#)

## DOSE
Dosage and administration should be discussed with the Clinical Haematologist
<table>
<thead>
<tr>
<th>ORDERING</th>
<th>Ordered on a named patient basis from Transfusion Medicine Unit (TMU).</th>
</tr>
</thead>
<tbody>
<tr>
<td>RECONSTITUTION</td>
<td><strong>CAUTION</strong> For instructions on reconstitution/filtration, refer to the individual product information and other supporting material accompanying the product. Before reconstitution allow the product to reach room temperature. Follow the instructions on the box inside lid/ARCBS leaflet regarding the use of the Mix2Vial transfer system or click on the link <a href="#">How to use the Mix2Vial</a>.</td>
</tr>
<tr>
<td>ADMINISTRATION</td>
<td>Two staff to perform checks as per the Clinical Practice Manual, <a href="#">WNHS Pharmacy Medication Checking and Administration</a> processes. Check Issue label and patient ID. Check right patient, right product, right dose – prescription matches product supplied. If not identical, contact TMU and prescribing doctor. Administer dose by slow intravenous infusion (approximately 3 mL per minute). Do not mix/piggy back this product with other medications or IV fluids/blood products.</td>
</tr>
<tr>
<td>OBSERVATIONS</td>
<td>Administer under constant visual observation. Monitor patient for at least 10 minutes post administration. Undertake observations as for all blood products. Vital signs (temperature, pulse, respiration, blood pressure) must be recorded on the observation chart in the medical record. Observe for signs of adverse reactions – see <a href="#">Thrombotrol®-VF Product Information</a>.</td>
</tr>
<tr>
<td>ADVERSE REACTIONS</td>
<td>Adverse reactions associated with ATIII concentrates include dizziness, chest tightness, foul taste in mouth, abdominal cramps, shortness of breath, light-headedness, hives, fever, and haematoma formation. If adverse reactions are experienced, the infusion rate should be decreased or, if indicated, the infusion should be interrupted until symptoms abate. For more information refer to the <a href="#">Product Information</a>. Any adverse reaction should be reported to the Clinical Haematologist/Microbiologist and TMU. Refer to <a href="#">WNHS Management of Transfusion Reactions and Adverse Events</a>, as a guide to further treatment and management of the patient.</td>
</tr>
</tbody>
</table>
## DOCUMENTATION

A record should be kept in the patient's history of the following:

- The date and time of infusion
- Patients observations and condition during the infusion
- Amount given
- The batch number and expiry date of each bottle used (place a sticker with the batch number on the Transfusion Medicine Record sheet MR735). This information is important should the patient have a reaction to the infusion or if there is a need to trace recipients of certain batch numbers at a later date.

For further information, refer to product insert. Return product to TMU immediately if no longer required. Product should be used for intended patient (issue label) only.

### References

- Australian Red Cross Blood Service – Blood products and transfusion practice for health professionals  

### Related policies


### Related WNHS policies, procedures and guidelines

<table>
<thead>
<tr>
<th><strong>File path:</strong></th>
<th>WNHS.HAEM.ThrombotrolVF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Keywords:</strong></td>
<td>Thrombotrol VF ATIII, antithrombin III concentrate, ATIII, indications for antithrombin III, antithrombin III indications, reconstitution of antithrombin III, plasma derived blood products, transfusion of plasma derived blood products, hereditary deficiency of anti-thrombin, blood products, mix 2 vial</td>
</tr>
<tr>
<td><strong>Document owner:</strong></td>
<td>Chair of KEMH Hospital Transfusion Committee</td>
</tr>
<tr>
<td><strong>Author / Reviewer:</strong></td>
<td>Consultant Haematologist, Scientist in Charge Transfusion Medicine, KEMH Transfusion Coordinator</td>
</tr>
<tr>
<td><strong>Date first issued:</strong></td>
<td>01 01 2005</td>
</tr>
<tr>
<td><strong>Last reviewed:</strong></td>
<td>01 12 2015</td>
</tr>
<tr>
<td><strong>Endorsed by:</strong></td>
<td>KEMH Hospital Transfusion Committee</td>
</tr>
<tr>
<td><strong>Standards Applicable:</strong></td>
<td>NSQHS Standards: 1 Governance, 5 Patient ID/Procedure Matching, 7 Blood Products</td>
</tr>
</tbody>
</table>

*Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.*